Open Access

Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma

  • Mira A. Patel1,
  • Jennifer E. Kim1,
  • Debebe Theodros1,
  • Ada Tam2,
  • Esteban Velarde3,
  • Christina M. Kochel2,
  • Brian Francica2,
  • Thomas R. Nirschl2,
  • Ali Ghasemzadeh2,
  • Dimitrios Mathios4,
  • Sarah Harris-Bookman4,
  • Christopher C. Jackson4,
  • Christina Jackson4,
  • Xiaobu Ye4,
  • Phuoc T. Tran2, 3, 6,
  • Betty Tyler4,
  • Vladimir Coric5,
  • Mark Selby5,
  • Henry Brem1, 4,
  • Charles G. Drake6,
  • Drew M. Pardoll2 and
  • Michael Lim1, 4Email author
Contributed equally
Journal for ImmunoTherapy of Cancer20164:74

https://doi.org/10.1186/s40425-016-0181-6

Received: 24 October 2016

Accepted: 25 October 2016

Published: 4 November 2016

The original article was published in Journal for ImmunoTherapy of Cancer 2016 4:28

Erratum

Unfortunately, after publication of this article [1], it was noticed that a funding source was not mentioned. Bristol-Myers Squibb was intended to be included in the ‘Financial Support’ section of the article.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
The Johns Hopkins University School of Medicine
(2)
Department of Oncology
(3)
Department Radiation Oncology
(4)
Department of Neurosurgery, The Johns Hopkins University School of Medicine
(5)
Bristol-Myers Squibb Company
(6)
The Brady Urological Institute

Reference

  1. Patel MA, Kim JE, Theodros D, Tam A, Velarde E, Kochel CM, Francica B, Nirschl TR, Ghasemzadeh A, Mathios D, Harris-Bookman S, Jackson CC, Jackson C, Ye X, Tran PT, Tyler B, Coric V, Selby M, Brem H, Drake CG, Pardoll DM, Lim M. Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. J Immunothera Cancer. 2016;4:28. doi:https://doi.org/10.1186/s40425-016-0132-2.View ArticleGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement